Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06013176 · ClinicalTrials.gov registry record · NA

Behavioral Economic Strategies to Improve PRO Adherence

A NA study of Cancer, sponsored by Abramson Cancer Center at Penn Medicine.

Completed
Registry status
NA
Development phase
476
Enrollment target
2
Study locations

NCT06013176: Completed NA study of Cancer, sponsored by Abramson Cancer Center at Penn Medicine.

NCT06013176 is a NA study of Cancer that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 476 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06013176, a NA study of Cancer, has completed, sponsored by Abramson Cancer Center at Penn Medicine.

COMPLETED
Registry status
NA
Development phase
476 participants
Enrollment target
2
Study locations

Study Summary

The main purpose of this research study is to evaluate the implementation and effectiveness of patient- and nurse-directed strategies across in-clinic and remote patient reported outcome (PRO) monitoring settings, using a three-arm pragmatic cluster randomized controlled trial. Additionally, the goal is to evaluate moderators of implementation effects on PRO monitoring. Eligible patients will be randomized independently to: (1) usual practice (i.e., encounter-based PRO administration via patient portal or tablet); (2) encounter-based PRO monitoring with patient reminders and nurse alerts; or (3) remote PRO monitoring with patient reminders and nurse alerts. The investigators hypothesize that nudges to patients and alerts to nurses will improve patient-level PRO completion and clinician-level PRO engagement.

Primary Outcome

The primary outcome will be PRO adherence, measured at the patient level as the proportion of expected PRO questionnaires completed per patient.

Conditions Studied

Interventions

  • OTHER Encounter-based PRO monitoring
  • OTHER Remote PRO monitoring

Study Locations (2)

New Jersey

  • Penn Medicine Princeton Health - Plainsboro

Pennsylvania

  • Abramson Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 476 participants
Start Date 2023-12-04
Est. Completion 2024-09-04
Phase NA

What the finished NCT06013176 record still lists

NCT06013176 is an interventional study that assigns participants to a tested intervention. The registered 476 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Encounter-based PRO monitoring is the first listed.

NCT06013176 reports a single indexed study location in New Jersey, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06013176 about?

NCT06013176 is a clinical study titled "Behavioral Economic Strategies to Improve PRO Adherence". The main purpose of this research study is to evaluate the implementation and effectiveness of patient- and nurse-directed strategies across in-clinic and remote patient reported outcome (PRO) monitoring settings, using a three-arm pragmatic cluster randomized controlled trial. Additionally, the goa...

What is the current status of trial NCT06013176?

This trial is currently completed. It is a NA study. The enrollment target is 476 participants. The study started on 2023-12-04. Estimated completion is 2024-09-04.

What conditions does trial NCT06013176 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT06013176?

The interventions under investigation include: Encounter-based PRO monitoring (OTHER), Remote PRO monitoring (OTHER).

Who is sponsoring clinical trial NCT06013176?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06013176 being conducted?

This trial has 2 study locations across New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06013176's enrollment target sits among peer trials

476 138th of 615 higher than 478 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06754046 · 476 participants · NA

    BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)

  • NCT03911700 · 477 participants · NA

    Prophylactic Reinforcement of Ventral Abdominal Incisions Trial

  • NCT06997497 · 477 participants · Phase 3

    A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  • NCT01788839 · 475 participants

    Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06013176, the US trial registry maintained by the National Library of Medicine. NCT06013176 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.